Cargando…

Short-Term Peg-IFN α-2b Re-Treatment Induced a High Functional Cure Rate in Patients with HBsAg Recurrence after Stopping Peg-IFN α-Based Regimens

Little is known about the treatment of patients with hepatitis B surface antigen (HBsAg) recurrence after being clinically cured by peginterferon alpha(peg-IFN-α)-based regimens. This study aimed to investigate the efficacy and safety of peg-IFNα-2b in re-treating patients with HBsAg recurrence afte...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Fengping, Wang, Yikai, Cui, Dandan, Tian, Yan, Lu, Rui, Liu, Chenrui, Li, Mei, Li, Yaping, Gao, Ning, Jiang, Zicheng, Li, Xuemei, Zhai, Song, Zhang, Xin, Jia, Xiaoli, Dang, Shuangsuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821570/
https://www.ncbi.nlm.nih.gov/pubmed/36615161
http://dx.doi.org/10.3390/jcm12010361
_version_ 1784865729122664448
author Wu, Fengping
Wang, Yikai
Cui, Dandan
Tian, Yan
Lu, Rui
Liu, Chenrui
Li, Mei
Li, Yaping
Gao, Ning
Jiang, Zicheng
Li, Xuemei
Zhai, Song
Zhang, Xin
Jia, Xiaoli
Dang, Shuangsuo
author_facet Wu, Fengping
Wang, Yikai
Cui, Dandan
Tian, Yan
Lu, Rui
Liu, Chenrui
Li, Mei
Li, Yaping
Gao, Ning
Jiang, Zicheng
Li, Xuemei
Zhai, Song
Zhang, Xin
Jia, Xiaoli
Dang, Shuangsuo
author_sort Wu, Fengping
collection PubMed
description Little is known about the treatment of patients with hepatitis B surface antigen (HBsAg) recurrence after being clinically cured by peginterferon alpha(peg-IFN-α)-based regimens. This study aimed to investigate the efficacy and safety of peg-IFNα-2b in re-treating patients with HBsAg recurrence after stopping peg-IFN α-based regimens. In this two-center, prospective observational study, 33 patients with HBsAg recurrence after stopping peg-IFN α-based regimens were enrolled and re-treated with an individualized course of peg-IFN α-2b. The hepatitis B virus (HBV) vaccine could be injected immediately after HBsAg clearance, according to patients’ willingness. All patients were monitored and followed-up for 48 weeks after peg-IFN α-2b re-treatment stop. The primary endpoint was HBsAg clearance at the end of follow-up. At baseline, all patients had HBsAg levels of <10 IU/mL and undetectable HBV DNA, with the median HBsAg level of 1.66 (0.56–2.87) IU/mL. After a median of 24 (24–30) weeks of peg-IFN α-2b re-treatment, 87.9% (29/33) of the patients achieved HBsAg clearance again and 66.7% (22/33) of the patients achieved HBsAg seroconversion. At the end of follow-up, the HBsAg clearance and HBsAg seroconversion rates decreased to 78.8% (26/33) and 51.5% (17/33), respectively. Furthermore, 88.9% (16/18) of the patients with HBsAg clearance benefited from receiving the HBV vaccine therapy. Generally, both peg-IFN α-2b and HBV vaccine therapy were well tolerated. A high functional cure rate can be achieved by a short-course of peg-IFN α-2b re-treatment in patients with HBsAg recurrence after stopping peg-IFN α-based regimens. Furthermore, injecting HBV vaccine is beneficial after HBsAg clearance.
format Online
Article
Text
id pubmed-9821570
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98215702023-01-07 Short-Term Peg-IFN α-2b Re-Treatment Induced a High Functional Cure Rate in Patients with HBsAg Recurrence after Stopping Peg-IFN α-Based Regimens Wu, Fengping Wang, Yikai Cui, Dandan Tian, Yan Lu, Rui Liu, Chenrui Li, Mei Li, Yaping Gao, Ning Jiang, Zicheng Li, Xuemei Zhai, Song Zhang, Xin Jia, Xiaoli Dang, Shuangsuo J Clin Med Article Little is known about the treatment of patients with hepatitis B surface antigen (HBsAg) recurrence after being clinically cured by peginterferon alpha(peg-IFN-α)-based regimens. This study aimed to investigate the efficacy and safety of peg-IFNα-2b in re-treating patients with HBsAg recurrence after stopping peg-IFN α-based regimens. In this two-center, prospective observational study, 33 patients with HBsAg recurrence after stopping peg-IFN α-based regimens were enrolled and re-treated with an individualized course of peg-IFN α-2b. The hepatitis B virus (HBV) vaccine could be injected immediately after HBsAg clearance, according to patients’ willingness. All patients were monitored and followed-up for 48 weeks after peg-IFN α-2b re-treatment stop. The primary endpoint was HBsAg clearance at the end of follow-up. At baseline, all patients had HBsAg levels of <10 IU/mL and undetectable HBV DNA, with the median HBsAg level of 1.66 (0.56–2.87) IU/mL. After a median of 24 (24–30) weeks of peg-IFN α-2b re-treatment, 87.9% (29/33) of the patients achieved HBsAg clearance again and 66.7% (22/33) of the patients achieved HBsAg seroconversion. At the end of follow-up, the HBsAg clearance and HBsAg seroconversion rates decreased to 78.8% (26/33) and 51.5% (17/33), respectively. Furthermore, 88.9% (16/18) of the patients with HBsAg clearance benefited from receiving the HBV vaccine therapy. Generally, both peg-IFN α-2b and HBV vaccine therapy were well tolerated. A high functional cure rate can be achieved by a short-course of peg-IFN α-2b re-treatment in patients with HBsAg recurrence after stopping peg-IFN α-based regimens. Furthermore, injecting HBV vaccine is beneficial after HBsAg clearance. MDPI 2023-01-02 /pmc/articles/PMC9821570/ /pubmed/36615161 http://dx.doi.org/10.3390/jcm12010361 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wu, Fengping
Wang, Yikai
Cui, Dandan
Tian, Yan
Lu, Rui
Liu, Chenrui
Li, Mei
Li, Yaping
Gao, Ning
Jiang, Zicheng
Li, Xuemei
Zhai, Song
Zhang, Xin
Jia, Xiaoli
Dang, Shuangsuo
Short-Term Peg-IFN α-2b Re-Treatment Induced a High Functional Cure Rate in Patients with HBsAg Recurrence after Stopping Peg-IFN α-Based Regimens
title Short-Term Peg-IFN α-2b Re-Treatment Induced a High Functional Cure Rate in Patients with HBsAg Recurrence after Stopping Peg-IFN α-Based Regimens
title_full Short-Term Peg-IFN α-2b Re-Treatment Induced a High Functional Cure Rate in Patients with HBsAg Recurrence after Stopping Peg-IFN α-Based Regimens
title_fullStr Short-Term Peg-IFN α-2b Re-Treatment Induced a High Functional Cure Rate in Patients with HBsAg Recurrence after Stopping Peg-IFN α-Based Regimens
title_full_unstemmed Short-Term Peg-IFN α-2b Re-Treatment Induced a High Functional Cure Rate in Patients with HBsAg Recurrence after Stopping Peg-IFN α-Based Regimens
title_short Short-Term Peg-IFN α-2b Re-Treatment Induced a High Functional Cure Rate in Patients with HBsAg Recurrence after Stopping Peg-IFN α-Based Regimens
title_sort short-term peg-ifn α-2b re-treatment induced a high functional cure rate in patients with hbsag recurrence after stopping peg-ifn α-based regimens
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821570/
https://www.ncbi.nlm.nih.gov/pubmed/36615161
http://dx.doi.org/10.3390/jcm12010361
work_keys_str_mv AT wufengping shorttermpegifna2bretreatmentinducedahighfunctionalcurerateinpatientswithhbsagrecurrenceafterstoppingpegifnabasedregimens
AT wangyikai shorttermpegifna2bretreatmentinducedahighfunctionalcurerateinpatientswithhbsagrecurrenceafterstoppingpegifnabasedregimens
AT cuidandan shorttermpegifna2bretreatmentinducedahighfunctionalcurerateinpatientswithhbsagrecurrenceafterstoppingpegifnabasedregimens
AT tianyan shorttermpegifna2bretreatmentinducedahighfunctionalcurerateinpatientswithhbsagrecurrenceafterstoppingpegifnabasedregimens
AT lurui shorttermpegifna2bretreatmentinducedahighfunctionalcurerateinpatientswithhbsagrecurrenceafterstoppingpegifnabasedregimens
AT liuchenrui shorttermpegifna2bretreatmentinducedahighfunctionalcurerateinpatientswithhbsagrecurrenceafterstoppingpegifnabasedregimens
AT limei shorttermpegifna2bretreatmentinducedahighfunctionalcurerateinpatientswithhbsagrecurrenceafterstoppingpegifnabasedregimens
AT liyaping shorttermpegifna2bretreatmentinducedahighfunctionalcurerateinpatientswithhbsagrecurrenceafterstoppingpegifnabasedregimens
AT gaoning shorttermpegifna2bretreatmentinducedahighfunctionalcurerateinpatientswithhbsagrecurrenceafterstoppingpegifnabasedregimens
AT jiangzicheng shorttermpegifna2bretreatmentinducedahighfunctionalcurerateinpatientswithhbsagrecurrenceafterstoppingpegifnabasedregimens
AT lixuemei shorttermpegifna2bretreatmentinducedahighfunctionalcurerateinpatientswithhbsagrecurrenceafterstoppingpegifnabasedregimens
AT zhaisong shorttermpegifna2bretreatmentinducedahighfunctionalcurerateinpatientswithhbsagrecurrenceafterstoppingpegifnabasedregimens
AT zhangxin shorttermpegifna2bretreatmentinducedahighfunctionalcurerateinpatientswithhbsagrecurrenceafterstoppingpegifnabasedregimens
AT jiaxiaoli shorttermpegifna2bretreatmentinducedahighfunctionalcurerateinpatientswithhbsagrecurrenceafterstoppingpegifnabasedregimens
AT dangshuangsuo shorttermpegifna2bretreatmentinducedahighfunctionalcurerateinpatientswithhbsagrecurrenceafterstoppingpegifnabasedregimens